ArticleBMJ open2019
Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Management of hidradenitis suppurativa in the inpatient setting: a clinical guide.Archives of dermatological research · 2025Guideline
- Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.The Journal of dermatology · 2021Trial
- Reducing non-attendance in hidradenitis suppurativa clinics: insights from a specialty service audit.Irish journal of medical science · 2026Article
- Insurance disparities in hidradenitis suppurativa: A comprehensive review of demographics, outcomes, and access to care.Dermatology online journal · 2026Review
- Patient journey and disparities in the diagnosis and treatment of patients with hidradenitis suppurativa.JID innovations : skin science from molecules to population health · 2026Article
- Characterizing barriers to care in patients with hidradenitis suppurativa.Dermatology online journal · 2026Article
- Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis.JAMA dermatology · 2025Article
- Diagnostic wandering in hidradenitis suppurativa: A nationwide cohort study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- The Impact of Surgery on Quality of Life in Hidradenitis Suppurativa: Results from a Prospective Single-Center Study.Life (Basel, Switzerland) · 2025Article
- Machine Learning for Early Detection of Hidradenitis Suppurativa: A Feasibility Study Using Medical Insurance Claims Data.JID innovations : skin science from molecules to population health · 2025Article
- Demographics, Comorbidity, Treatment, Healthcare Resource Utilization, and Costs Analysis of Hidradenitis Suppurativa in Dubai.Dermatology (Basel, Switzerland) · 2025Article
- A Claims-Based Algorithm for Identifying Hidradenitis Suppurativa Severity.Clinical epidemiology · 2025Article
- New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study.Life (Basel, Switzerland) · 2024Article
- Comparison of Negative Pressure Wound Therapy with or without a Split-Thickness Skin Graft in the Surgical Management of Axillary Hidradenitis Suppurativa: A Retrospective Cohort Study.Plastic surgery (Oakville, Ont.) · 2024Article
- Evaluating minority representation across health care settings in hidradenitis suppurativa and psoriasis.International journal of women's dermatology · 2024Article
- Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach.Frontiers in medical technology · 2024Article
- Characterizing emergency department charges for hidradenitis suppurativa: a retrospective cohort study of 55,868 visits, 2015-2019.Archives of dermatological research · 2023Article
- Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study.American journal of clinical dermatology · 2023Article
- Article
- Characteristics and treatment pathways in pediatric and adult hidradenitis suppurativa: An examination using real world data.JAAD international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHidradenitis suppurativa (HS) causes substantial morbidity and quality-of-life impairment. We examined demographic/clinical characteristics of patients with HS and treatment patterns, prevalence and healthcare resource utilisation/expenditures related to HS in the real-world.
designRetrospective claims data of MarketScan Commercial, Medicare Supplemental and Medicaid databases (2009-2014).
settingUSA.
participantsPatients aged ≥12 years with ≥3 non-diagnostic outpatient or inpatient claims with an HS diagnosis code and ≥12 months continuous enrolment with medical and pharmacy benefits before (preindex) and after (postindex) the earliest diagnosis of HS (index) were included.
resultsThere were 11 325 Commercial/Medicare patients (mean age 37.4 years) and 5164 Medicaid patients (mean age 28.3 years). HS was more common in Medicaid than Commercial/Medicare patients (0.301% and 0.098%, respectively, in 2014). Cellulitis and psychiatric disorders were the most common comorbidities and oral antibiotics and narcotics were the most frequently prescribed drugs preindex, with ≥10% increase postindex in both populations. HS-related inpatient costs decreased while outpatient costs increased from preindex to postindex. Medicaid patients had several risk factors that may be associated with poor outcomes (eg, high rates of prescription pain medication use, comorbidities, drug discontinuation/interruption/holiday, emergency department (ED) visits and hospitalisation).
conclusionsCommercial/Medicare and Medicaid HS beneficiaries experience high comorbidity burden but use different treatment modalities to manage HS. Results suggest a substantial unmet need exists among this patient population, with Medicaid patients experiencing a particularly high burden of disease and expensive healthcare resource utilisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.